June 13, 2019 / 5:49 PM / 4 months ago

BRIEF-Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA

June 13 (Reuters) - U.S. FDA:

* AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE

* U.S. FDA SAYS KANJINTI (TRASTUZUMAB-ANNS) IS BIOSIMILAR TO HERCEPTIN (TRASTUZUMAB)

* U.S. FDA SAYS KANJINTI COMES WITH A BOXED WARNING FOR CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, PULMONARY TOXICITY Source text: (bit.ly/2RdhYiI) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below